Stand Up To Cancer - standuptocancer.orgThis is where the end of cancer begins
   Please leave this field empty

SU2C Scientific Research Teams

Share this:

Like this page on Facebook

Lecia Sequist, MD, MPH

Scientific Research Team:
Lecia Sequist, MD, MPH

Lecia Sequist, MD, MPH

The leader of the SU2C-LUNGevity Foundation-American Lung Association Lung Cancer Interception Translational Research Team is Lecia Sequist, MD, MPH, the Landry Family associate professor of medicine at Harvard Medical School and the director of the Center for Innovation in Early Cancer Detection at Massachusetts General Hospital (MGH). Dr. Sequist is a medical oncologist, and a seasoned clinical and translational scientist who has significant experience designing and managing multi-center clinical trials in lung cancer with a track record coordinating large biosample collections in her role as the lead clinical collaborator for the MGH circulating tumor cell (CTC) chip development over the past decade. Her research as a clinical/translational scientist has focused for the last ten years on lung cancer, clinical trials, acquired resistance to targeted therapeutics, and liquid biopsies for cancer patients using CTCs and ctDNA.